Business
AstraZeneca agrees obesity and T2D deal with CSPC
AstraZeneca has entered into a strategic collaboration with CSPC Pharmaceuticals to advance its weight management portfolio, acquiring global rights outside of China to eight programmes, including a clinical-ready asset, SYH2082, a long-acting GLP1R/GIPR agonist. This agreement grants AstraZeneca access to CSPC's AI-driven peptide drug discovery platform and LiquidGel once-monthly dosing technology, for which AstraZeneca will pay an upfront payment of $1.2 billion, with potential development and regulatory milestones up to $3.5 billion, plus commercialisation milestones and tiered royalties. The transaction is expected to close in the second quarter of 2026, enhancing AstraZeneca's pipeline of next-generation obesity treatments. Disclaimer*
About this update from Astrazeneca Plc
[{"type":"text","content":"\n\n30 January 2026\n \nAstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals\n \nAgreement includes eight programmes, including a clinical-ready asset, plus access to advanced AI-driven peptide drug discovery platform and innovative monthly dosing technology \n \nAstraZeneca strengthens its weight management portfolio through a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across eight programmes. Under this agreement, the companies will initially progress four programmes, which utilise CSPC's advanced AI-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing platform technology. \n \nAstraZeneca will receive exclusive global rights outside of China to CSPC's once-monthly injectable weight management portfolio, comprising one clinical-ready asset, SYH2082, a long-acting GLP1R/GIPR agonist progressing into Phase I and three preclinical programmes with differing mechanisms designed to provide extended therapeutic benefits for people living with obesity and weight-related conditions. \n \nSharon Barr, Executive Vice President and Head of BioPharmaceuticals R&D, AstraZeneca, said: \"This strategic collaboration advances our weight management portfolio by delivering novel assets which complement our existing programmes. It will provide access to CSPC's proprietary AI-enabled peptide capabilities and platform technology, which have the potential to transform the treatment of obesity, helping to address adherence and convenience as key barriers to long-term therapeutic success. This is an important step in creating a portfolio of simple, scalable and sustainable options that can help people with obesity, and weight-related complications live better, healthier lives.\"\n \nDongchen Cai, Chairman of the Board, CSPC Pharmaceutical Group Ltd, said \"We are very excited to further expand and strengthen our strategic partnership with AstraZeneca into the area of weight management. Obesity and related comorbidities represent a significant health challenge but also an opportunity. We hope this win-win collaboration will deliver the next generation of treatments that build upo...